Gustave Roussy and Paris Sud University, Paris, France.
Trends Mol Med. 2017 Nov;23(11):983-985. doi: 10.1016/j.molmed.2017.09.008.
How can we transform an immune desert into a 'hot tumor' that is prone to respond to anti-programmed death (PD)-1 immunotherapy? This might be possible by injecting an oncolytic virus, engineered to induce local immune stimulation, prior to anti-PD-1 therapy. A recent study demonstrated that this combination - evaluated in a Phase Ib metastatic melanoma clinical study - yields promising results.
如何将免疫荒漠转化为易于对抗程序性死亡 (PD)-1 免疫疗法产生应答的“热肿瘤”？通过在抗 PD-1 治疗之前注射一种经工程改造以诱导局部免疫刺激的溶瘤病毒，这可能成为现实。最近的一项研究表明，这种组合 - 在转移性黑色素瘤的 Ib 期临床试验中进行了评估 - 产生了有希望的结果。
